Investment
Features
FeesSafety
Academy
More
Pluang+

Flex to spin off Power and Cloud unit into two focused public companies by early 2027

Company Fundamentals
05 May 2026
PRNewsWire
View Source
Bullish
pluang ai news

Flex announced a plan to spin off its Power and Cloud portfolio into a new independent company, SpinCo, focused on digital infrastructure for AI data centers, while Flex will continue as a global advanced manufacturing firm. The spin-off aims to sharpen strategic focus, improve financial clarity, and create shareholder value, with SpinCo targeting rapid revenue growth and Flex focusing on manufacturing solutions across diverse industries. Leadership changes include Revathi Advaithi as SpinCo CEO and Michael Hartung as Flex CEO. The transaction is expected to be tax-free and close in the first quarter of 2027.

More News

UBS Group AG surpasses 5% ownership in Bang & Olufsen shares as of July 9, 2026

UBS Group AG surpasses 5% ownership in Bang & Olufsen shares as of July 9, 2026

UBS Group AG has officially reported holding 7,676,171 shares in Bang & Olufsen A/S, representing 5.21% of the company's total share capital and voting rights as of July 9, 2026. This notification is made under the Danish Capital Markets Act, signali...

Market News
Neutral
41 minutes ago
Global hazardous area equipment market to nearly double to $25.28B by 2035, driven by safety regulations and smart tech.

Global hazardous area equipment market to nearly double to $25.28B by 2035, driven by safety regulations and smart tech.

The global hazardous area equipment market, valued at $13.5 billion in 2025, is projected to reach $25.28 billion by 2035, growing at a CAGR of 6.48%. Growth is fueled by stricter industrial safety regulations like ATEX and OSHA, and the adoption of ...

Market News
Bullish
1 hour ago
FDA grants Priority Review to Roche's Gazyva for primary membranous nephropathy treatment

FDA grants Priority Review to Roche's Gazyva for primary membranous nephropathy treatment

The FDA has granted Priority Review to Roche's Gazyva (obinutuzumab) for treating primary membranous nephropathy (pMN), a chronic autoimmune kidney disease with no current FDA-approved therapies. This decision follows positive phase III MAJESTY trial...

Market News
Bullish
4 hours ago
Trinity Capital rated 'Buy' for strong 11.8% yield and resilient portfolio despite economic risks

Trinity Capital rated 'Buy' for strong 11.8% yield and resilient portfolio despite economic risks

Trinity Capital is recommended as a 'Buy' due to its consistent outperformance against major indices and a strong 11.8% yield. The company maintains a diversified portfolio across technology, equipment financing, and life sciences, supporting steady ...

Analyst Insights
Bullish
4 hours ago
ASML reports €9.3B Q2 sales, raises 2026 sales outlook to €43-45B with strong AI-driven chip demand.

ASML reports €9.3B Q2 sales, raises 2026 sales outlook to €43-45B with strong AI-driven chip demand.

ASML reported strong Q2 2026 results with €9.3 billion in net sales and €2.9 billion in net income, surpassing guidance due to higher Installed Base Management sales. The company raised its 2026 total net sales forecast to between €43 billion and €45...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App